Every weekday morning, 21,000 neuroscientists, clinicians, and brain-obsessed readers open SIGNAL — the free briefing on the biology of the mind, the mysteries of consciousness, and what your neurons are doing right now while you read this.
By subscribing you agree to receive SIGNAL and service updates from Signal Media, Inc. Unsubscribe anytime. All protocols below.
The hard problem of consciousness is called "hard" because it is genuinely unsolved, not because scientists haven't tried. A review of the four dominant competing frameworks — and what the most recent experimental evidence does and doesn't resolve about the relationship between neural activity and subjective experience.
Memory reconsolidation — the process by which retrieved memories become temporarily unstable — has moved from a theoretical curiosity to a clinical target. New trials of propranolol-assisted trauma therapy and reconsolidation-based interventions are producing results that challenge the consensus on PTSD treatment.
The glymphatic system — the brain's waste-clearance network — operates primarily during slow-wave sleep, flushing metabolic byproducts including amyloid-β. New imaging data shows the relationship between sleep architecture and clearance efficiency more precisely than previously possible, with direct implications for Alzheimer's prevention research.
Whether adult humans generate new neurons in the hippocampus is one of the most disputed questions in neuroscience. The disagreement is not about methodology failure — it's about what counts as a neuron, what counts as new, and what the hippocampus is even for. SIGNAL explains what both sides are actually arguing.
SIGNAL covers neuroscience as a rigorous empirical discipline with urgent clinical and philosophical consequences — not as wellness advice, not as pop psychology, and not as hype about brain-computer interfaces. One finding, fully explained, every weekday morning.
One peer-reviewed neuroscience result — with sample sizes, methods, and honest caveats about what the study actually shows.
How the biology actually works — the circuits, the molecules, the pathways — explained at the level of precision that makes the finding meaningful.
What the study doesn't prove — and what you should be sceptical about before accepting the interpretation the press release offered.
One careful claim about what the finding suggests for clinical practice, for philosophy of mind, or for our understanding of ourselves.
All protocols approved and in force. Effective January 1, 2026 · Amended April 1, 2026 · By subscribing to SIGNAL you consent to the practices described in these protocols.
Signal Media, Inc. ("we") collects only the email address voluntarily provided by the subscriber ("participant") at enrolment. No names, phone numbers, addresses, or payment details are collected. Anonymised server logs (country, browser type, referral URL) may be retained for up to 30 days for operational purposes only.
The participant's email address is used solely to: (a) deliver the SIGNAL newsletter on weekday mornings; (b) transmit infrequent service notices, not to exceed four per calendar year; and (c) measure aggregate, anonymised engagement metrics for editorial quality. The address is shared only with our contracted email service provider under a formal data processing agreement. It is never sold, rented, or disclosed to any other party. Suppressed within 10 days of withdrawal; deleted within 90 days.
Participants have the right to access, correct, port, or delete their data at any time. EU/UK participants: see Protocol SIG-POL-07. California participants: see Protocol SIG-POL-07. No tracking cookies are placed. One strictly necessary session cookie expires upon browser close. This protocol does not apply to persons under 16. Contact: privacy@signalmail.news · Signal Media, Inc. · 1 Infinite Loop, Suite 500, San Francisco, CA 94105, USA.
These Terms constitute the conditions of participation for the SIGNAL newsletter, operated by Signal Media, Inc. By subscribing or visiting this site, participants agree to these Terms in full.
SIGNAL content is published for informational and educational purposes only. It does not constitute professional neuroscientific, medical, psychological, or clinical advice. Participants should not make significant health decisions based solely on SIGNAL content without consulting a qualified healthcare professional.
All original SIGNAL content is © 2026 Signal Media, Inc. Non-commercial sharing with attribution is permitted. The following activities are prohibited: commercial use without a written licence; systematic scraping or republication; submission of false participant information; unauthorised access to systems; automated harvesting. Total aggregate liability shall not exceed USD $10.00. Governed by California law; San Francisco County courts. Contact: legal@signalmail.news
Participants receive the SIGNAL newsletter Monday through Friday, delivered 6:00–8:00 AM local time, plus infrequent service notices not exceeding four per calendar year. No promotional communications or undisclosed sponsored content are transmitted. Sponsored content is clearly labelled "Sponsored."
Participants may withdraw from the study at any time via a one-click unsubscribe link included in every communication (CAN-SPAM & GDPR compliant). Withdrawal results in immediate suppression. Alternatively, participants may contact unsubscribe@signalmail.news; withdrawal will be processed within two business days. Physical address in every communication: 1 Infinite Loop, Suite 500, San Francisco, CA 94105, USA. The legal basis for all communications is explicit opt-in consent (GDPR Art. 6(1)(a)); the date, time, and IP address of each enrolment are recorded.
SIGNAL maintains full editorial independence from all commercial, academic, and institutional interests. Story selection is determined solely by scientific merit and participant value. Sponsors, pharmaceutical companies, and neurotechnology firms have no editorial influence. We use peer-reviewed journals, published clinical trial data, pre-registered studies, and direct expert commentary. Pre-prints are identified and treated with appropriate caution. Errors are corrected in the subsequent issue with a clear notation; archives are not silently altered. Corrections contact: corrections@signalmail.news. Subscriber figures reflect verified active subscribers per our ESP's monthly audit.
A single strictly necessary session cookie is placed for form functionality purposes only. This cookie contains no personal data and expires upon closure of the browser session. No tracking, advertising, retargeting, or analytics cookies are placed on this page. No third-party scripts or social media software development kits are loaded. No consent banner is required under EU/UK GDPR or the ePrivacy Directive. Participants may block or delete cookies at any time via browser settings; this may affect form functionality. Contact: privacy@signalmail.news
All original SIGNAL content is © 2026 Signal Media, Inc. All rights reserved. Permitted uses include: sharing links; quoting up to 50 words with attribution for non-commercial purposes; and academic citation per standard bibliographic conventions. All other reproduction requires written permission from Signal Media, Inc. DMCA takedown notices must be submitted in writing to dmca@signalmail.news and must include: (1) identification of the copyrighted work; (2) location of the infringing material; (3) the submitter's contact information; (4) a good-faith belief statement; and (5) a statement under penalty of perjury confirming accuracy and authority. Physical address for notice: 1 Infinite Loop, Suite 500, San Francisco, CA 94105, USA. Counter-notifications are accepted and assessed in good faith.
California residents hold the following rights: (a) the right to know what personal information is collected and how it is used; (b) the right to deletion; (c) the right to opt out of sale of personal information (Signal Media, Inc. does not sell personal data); (d) the right to non-discrimination for exercising the foregoing rights. Requests should be directed to privacy@signalmail.news with subject line "CCPA Request." Response will be provided within 45 days.
EU and UK data subjects hold the following rights: access, rectification, erasure, portability, restriction of processing, objection to processing, withdrawal of consent without affecting prior lawful processing, and the right to lodge a complaint with a supervisory authority (e.g., ICO in the UK). Our legal basis for processing is explicit opt-in consent (GDPR Art. 6(1)(a)). Contact: privacy@signalmail.news — response within 30 days.
Signal Media, Inc. is committed to making this website and the SIGNAL newsletter accessible to all participants, including those with disabilities. We target conformance with WCAG 2.1 Level AA. Implemented measures include: semantic HTML with correct heading hierarchy; programmatic and visible form field labels; sufficient colour contrast across all text; keyboard-navigable interactive elements with visible focus indicators; ARIA roles on all dynamic content; and a plain-text newsletter alternative available on request. Accessibility feedback should be directed to accessibility@signalmail.news. Response will be provided within five business days; identified issues will be resolved within 30 days where technically feasible.